CTIS2023-508440-21-00进行中（未招募）1 期
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generationcephalosporin-resistant Enterobacterales (ASTARTÉ):randomised, pragmatic trial - ASTARTÉ
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla0 个研究点目标入组 334 人开始时间: 2024年5月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 334
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Hospitalized adult patients (18 years or older) who present bacteremia of any origin with monomicrobial isolation of Enterobacterales in blood culture; Patients with polymicrobial bacteremia caused by more than one enterobacteria may also be included, with at least one of them being resistant to third-generation cephalosporins (see next point), and both being sensitive to meropenem and temocillin., The microorganism is resistant to third generation cephalosporins: cefotaxime, ceftriaxone (MIC > 2 mg/L) and/or ceftazidime (MIC > 4 mg/L)., The microorganism is sensitive to temocillin (MIC =8 mg/L, except in bacteremia of urinary origin only, for which the criterion is MIC =16 mg/L) and meropenem (MIC =2 mg/L)., Patients in whom, once diagnosed with potentially includable Enterobacterales bacteremia, the need to maintain intravenous treatment is estimated for at least 4 days from randomization, or 3 days if empirical treatment prior to randomization was appropriate., Patients who have signed the informed consent., Potentially fertile patients must have a negative pregnancy test.
排除标准
- •Minors under 18 years of age., Terminal situation, or estimated life expectancy of less than 30 days, or under purely palliative treatment for their underlying illness, so that necessary actions will not be taken to control the focus of infection if necessary. Patients in palliative care and with a life expectancy greater than 30 days may be included, in which control of the focus is not necessary or, if necessary, will be carried out., Pregnant or breastfeeding women., Known allergy or hypersensitivity to beta-lactams, Polymicrobial bacteremia (except when the other microorganism is considered a contaminant, such as coagulase-negative staphylococci or diphtheroids in a single extraction, or in the case of isolation of more than one enterobacteria, provided that the criterion that at least one of them is resistant to third generation cephalosporins, and both sensitive to meropenem and temocillin)., Delay in inclusion greater than 48 hours after having the antibiotic sensitivity data of the Enterobacteriaceae isolated in blood culture, or who have received active empirical treatment for more than 96 hours after the initial blood culture was obtained., Infections that typically have a recommended treatment duration of more than 14 days (endocarditis, osteomyelitis, prosthetic infection, chronic prostatitis, empyema...), or meningitis. Patients who initially do not have a confirmed diagnosis of these infections may be included; If their diagnosis is made later, the patient may be kept in the trial at the discretion of the researcher, establishing the duration of treatment that is considered necessary., Peritoneal dialysis or continuous hemofiltration., Patients who are participating in another clinical trial with active treatment.
研究者
相似试验
进行中（未招募）
1 期
AEUCTR2017-001257-14-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)350
进行中（未招募）
1 期
Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS)Septic Shock, SepsisCTIS2023-509703-33-00Rigshospitalet400
已完成
3 期
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen CephalosporinsBacteremiaNCT04478721Fundación Pública Andaluza para la gestión de la Investigación en Sevilla334
进行中（未招募）
1 期
Temocillin use in Complicated Urinary Tract Infections due to ESBL producing and AmpC hyperproducing Enterobacteriaceae in United Kingdom - TEA trialEUCTR2008-005912-41-GBBelpharma SA/NV50
尚未招募
不适用
Comparison of 2 antibiotics in treatment of ventilator induced lung infectiopCTRI/2024/01/062000ot applicable